| Literature DB >> 30621965 |
Hugo De Larochellière1, Rishi Puri2, John W Eikelboom3, Josep Rodés-Cabau4.
Abstract
Transcatheter aortic valve replacement (TAVR) is well established for treating patients with severe aortic stenosis considered at intermediate to high surgical risk. Blood disorders such as anemia, thrombocytopenia, and acquired type 2A von Willebrand disease are relatively frequent in TAVR candidates, and multiple studies to date have highlighted their potential clinical association with mortality and/or bleeding complications post-TAVR. The present review provides an overview of various blood disorders observed pre- and post-TAVR, with special focus on their incidence, etiology, clinical association, and management.Entities:
Keywords: anemia; aortic stenosis; hemostasis; thrombocytopenia
Year: 2019 PMID: 30621965 DOI: 10.1016/j.jcin.2018.09.041
Source DB: PubMed Journal: JACC Cardiovasc Interv ISSN: 1936-8798 Impact factor: 11.195